Record PAT but revenue growth trailing 20% target
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met profitability targets (EBITDA margin 27.48% vs 25%); beat prior PAT guidance (₹117 Cr). Missed revenue growth guidance (12% actual vs 20% target).
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong execution on profitability (PAT +30%, EBITDA margin 27.48% beats 25% target) and capacity expansion (Phase-1 complete). But revenue growth of 12% YoY and H1 at ~15% trails the reaffirmed 20% guidance, leaving H2 with a steep 25%+ growth requirement. Phase-2 ramp delayed to H2 FY28; regulatory approvals on Fine Sciences merger pending.
₹760.5 Cr
Revenue · +12% YoY₹117.5 Cr
Reported PAT · +30.3% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Record quarterly revenue and profitability
OVERSTATED₹760.5 Cr revenue (+12% YoY), ₹117.5 Cr PAT (+30.3% YoY) — record PAT, but revenue growth lags 20% target
Maintain 20% growth guidance overall in coming years
MISSH1 FY27 grew ~15% (implied from statement), Q2 at 12% YoY — trajectory shows 20% FY27 exit requires H2 at 25%+
EBITDA margin 27.48% as against 26.12% prior H1
OVERSTATEDOPM delivered 26.3%; EBITDA of ₹212.49 Cr claimed, but structured analysis shows ~₹200 Cr — benefited by ₹1.62 Cr state incentives
Phase-1 expansion (48K→54K MT) completed by Sep 2026
METConfirmed completed; ramp-up 85–90% utilization expected in Q4 FY27 when new contracts start
20% or beating 20% confidence for FY27-28
MISSBased on H1 miss (15%), guidance math is tight; Phase-2 revenue only starts H2 FY28, not FY27
Earnings quality
What changed since the last call
Phase-1 expansion status
UpgradeWas delayed to Sep 2026 in prior call; now completed on schedule as of Sep 30. Ramp to 85–90% utilization in Q4.
EBITDA margin guidance
UpgradePrior guidance: sustain ~25%. Delivered: 27.48% in Q2 FY27. Structural improvement from cost discipline and higher-value product mix.
Revenue growth track
DowngradeGuided 20% growth; H1 at ~15%, Q2 at +12% YoY. Analysts pushed back (Ram Arvind, iThoughtPMS) on math to hit 20% exit. Management defended seasonality but no new numeric proof.
Fine Sciences merger timeline
WithdrawnPrior target: ₹100 Cr revenue by FY25. Actual FY26: ₹68 Cr. Now awaiting regulatory approvals with vague 'next FY' completion guidance. Target not reset publicly.
JV revenue contribution
NewJV turned profitable in Q2 FY27 (₹28 Cr revenue). Now guiding ₹225 Cr for FY27-28 and Phase-3 pilot studies underway.
The Q&A
Firm analyst pushback on 20% guidance. Ram Arvind (iThoughtPMS) directly challenged math: H1 at 15% growth would require H2 at 25%+ to hit 20% FY27. Narayan reaffirmed guidance citing seasonal patterns (H2 stronger) but did not provide forward-looking order book or volume drivers. Overall, management held the line on guidance despite visible skepticism.
Phase-1 debottlenecking ramp — Krish Salot, Veer Growth AIF
AnsweredExpansion completed. Part coming in Q3, significant part in Q4. Expect 85–90% capacity utilization in Q4 for expanded capacity.
20% revenue growth guidance — Ram Arvind, iThoughtPMS
PartialStill maintain 20% guidance. First half normally lower, second half stronger. Annual basis you look at us; very confident 20% annual.
Growth segment drivers — Ram Arvind, iThoughtPMS
DodgedDo not give segmental guidance. But overall, will maintain 20% growth.
Raw material and freight pressure — Mahima Gidwani, PhillipCapital PMS
Answered2/3 revenue from non-petroleum sources, ~70% resilient. Freight: learned from past mistakes; now quarterly pricing mechanism with customers. Not faced extent of disturbance others face.
CST and GTO sourcing concentration — Divesh Chainani, Equentis
PartialVery diversified sourcing.
JV revenue guidance — Divesh Chainani, Equentis
Answered2 phases of expansion; one underway. Expect ₹225 Cr revenue. Also 3rd phase pilot studies underway.
Capex plan and revenue roadmap — Anirudh Sharma, Ekaant Investments
AnsweredPhase-1 completed ₹450 Cr. Phase 2 and 3 expect ₹1,000 Cr capex. 3 phases combined potential ₹1,700–1,800 Cr revenue. By 2030, should hit ₹5,000 Cr.
Fine Sciences merger status — Krish Salot, Veer Growth AIF
PartialFine Sciences at ₹68 Cr FY26. 5 products, 4 already supplied to multinationals. Regulatory approvals pending. Next year significant improvement expected.
Working capital improvement — Nikhil Porwal, Perpetual Capital
AnsweredDefinitely this time. Long-term, expect 105–110 days broadly.
Other income drivers — Nirav Gandhi, Sunidhi Securities
AnsweredExports high, dollar in favor. Net exporter, helps. Other income consists major part FX gains.
State incentive receipt timeline — Sudhir Bheda, Bheda Family Office
AnsweredH1 received ₹1.62 Cr (vs ₹9 Cr prior year). Expect more in next 6 months. Range ₹12–15 Cr total expected.
FY27-28 guidance — Sudhir Bheda, Bheda Family Office
PartialPositive outlook. Confident maintaining 20% or beating 20%. Close to ₹4,000 Cr maybe ₹3,750 or some number. EBITDA margin where we are right now.
Guidance
20% CAGR to ₹5,000 Cr by 2030
MediumReaffirmed from prior call. But H1 FY27 at ~15%, Q2 at +12% YoY suggests near-term execution risk.
FY27-28 guidance ₹3,750–4,000 Cr revenue
MediumImplies 15–20% growth from FY27 base; Phase-2 contribution only from H2 FY28, so upside limited
Phase-2 revenue ₹1,000+ Cr at full capacity (12K MT)
MediumPhase-2 capex ₹400–odd Cr, commercials Jun–Sep 2027, but full ramp into FY28–29
EBITDA margin sustain ~25%
HighQ2 delivered 27.48%, exceeding target. Structural OPM 26.3%. Mix benefit from new higher-value products.
Phase 2 & 3 combined: ₹1,000 Cr capex (Phase 1 ₹450 Cr completed)
HighPhase 2 expected ₹400–odd Cr (66K MT capacity), Phase 3 ₹400–425 Cr. Timeline: Phase 2 Jun–Sep 2027, Phase 3 pilot stage
Risks the call surfaced
Revenue growth miss
HighH1 FY27 at ~15%, Q2 at +12% YoY. To hit 20% FY27 requires H2 at 25%+. Management defending guidance but no new order book data provided. Phase-2 revenue deferred to H2 FY28.
Regulatory approval delays
MediumFine Sciences revenue stuck at ₹68 Cr (FY26) vs ₹100 Cr target. Merger regulatory approvals pending; timeline vague ('next FY'). Capacity expansion limited by approvals.
Geopolitical and logistics risk
MediumExtended West Asia war scenarios mentioned. Freight costs volatile. Though 70% of input from non-petroleum sources limits exposure.
FX and incentive dependency
LowH1 benefited from ₹1.62 Cr state incentives (vs ₹9 Cr prior year, down 82%) and FX gains (large net exporter). Margin benefit may not sustain if dollar weakens.
Segment concentration (Pinene)
MediumPinene is largest segment; management withheld segment-level disclosure. Africa market and new applications are growth drivers, but no volume or % breakdown. Heavy dependence on pinene concentration.
Management
Score 7/10. Clear on financial metrics and roadmap (Phase 1-3 capex, 5K vision by 2030). Transparent on cash flow and balance sheet. Evasive on segment disclosure and near-term growth math. Met EBITDA and profitability targets; beat PAT guidance. Missed revenue growth guidance (12% vs 20%). Phase-1 on time; Phase-2 and Fine Sciences delayed. Track record mixed.
1 · Q3 FY27 (Oct–Dec)
New debottlenecking contracts ramp; Phase-1 capacity utilization target 85–90%
2 · Q4 FY27 (Jan–Mar 2027)
Significant volume growth from expanded capacity; ₹12–15 Cr remaining incentive inflow
3 · Jun–Sep 2027
Phase-2 commercial production begins; targeted ₹225 Cr JV revenue by FY27-28
Phase-2 ramp delayed to H2 FY28; regulatory approvals on Fine Sciences merger pending.
Informational and educational content only. Not investment advice.